AgingResearch.NewsJoin free

Biomodulina T

Biomodulina T has been studied in 3 papers since 2020: 1 trial in people, 2 reviews. The newest paper, Apr 20, 2023: “History of the discovery and development of Biomodulina T (InmunyVital®), a useful immunomodulator with a broad range of clinical applications”.

Intervention

3 papers study it6 findingsUpdated

See all 3

“subpopulations of B lymphocytes and natural cytotoxic T (NKT) cells increased only with the administration of BT.”
Effect of Biomodulina-T® and VA-MENGOC-BC® on lymphocyte subpopulations in older adultsExperimental gerontology2021doi:10.1016/j.exger.2021.111497

None of its findings points the other way.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • 2 of 2 findings with company ties
  • Human trial1

Studies in people

1 study gave biomodulina T to people and measured what changed.

  • up: Increases B lymphocytes

    up: Increases natural cytotoxic T cells

    Trial30 peopleover 65 years of age

    Older adults

    Experimental gerontology, Jul 26, 2021

What did studies of Biomodulina T find?

6

Studies of Biomodulina T measured 6 outcomes; the most studied are healthspan (1 study), thymus size (1) and natural cytotoxic T cells (1).

Healthspan

upin humans1

1 study

  1. Biomodulina T improves healthspan in humans.

    “improving healthspan in aging”

    Review

    History of the discovery and development of Biomodulina T (InmunyVital®), a useful immunomodulator with a broad range of clinical applications

    International immunopharmacology

Thymus size

upin humans1

1 study

  1. Biomodulina T increases thymus size in children with thymic hypoplasia.

    “promotes the recovery of normal thymus size in children with thymic hypoplasia”

    Reviewin children with thymic hypoplasia

    History of the discovery and development of Biomodulina T (InmunyVital®), a useful immunomodulator with a broad range of clinical applications

    International immunopharmacology

Natural cytotoxic T cells

upin humans1

1 study

  1. Biomodulina T increases natural cytotoxic T cells in humans.

    “subpopulations of B lymphocytes and natural cytotoxic T (NKT) cells increased only with the administration of BT.”

    Human trialn = 30

    Effect of Biomodulina-T® and VA-MENGOC-BC® on lymphocyte subpopulations in older adults

    Experimental gerontology

More on Natural cytotoxic T cells

B lymphocytes

upin humans1

1 study

  1. Biomodulina T increases B lymphocytes in humans.

    “subpopulations of B lymphocytes and natural cytotoxic T (NKT) cells increased only with the administration of BT.”

    Human trialn = 30

    Effect of Biomodulina-T® and VA-MENGOC-BC® on lymphocyte subpopulations in older adults

    Experimental gerontology

More on B lymphocytes

CD4-positive T-cell proliferative capacity

upin humans1

1 study

  1. Biomodulina T increases CD4-positive T-cell proliferative capacity in humans.

    “the proliferative capacity of CD4-positive T lymphocytes increases, without changes in the frequency of regulatory T lymphocytes”

    Review

    Biomodulina T May Restore Immunity in Older Adults

    MEDICC review

More on CD4-positive T-cell proliferative capacity

PD-1 expression in CD4-positive T lymphocytes

downin humans1

1 study

  1. Biomodulina T decreases PD-1 expression in CD4-positive T lymphocytes in humans.

    “the expression of programmed cell death 1 protein in CD4-positive T lymphocytes and CD4-positive T lymphocytes decreases”

    Review

    Biomodulina T May Restore Immunity in Older Adults

    MEDICC review

More on PD-1 expression in CD4-positive T lymphocytes

Latest

Related